Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma

Recruiting Phase 1 Phase 2 Interventional Study
Hepatocellular Carcinoma
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 1/2
Study type
Interventional
Purpose
Treatment
Participants needed
93 (estimated)
Sponsor
VA Office of Research and Development · Federal
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Trans-arterial chemoembolization (TACE) is the most commonly used therapy for patients with unresectable hepatocellular carcinoma (HCC). TACE is a minimally invasive procedure that involves placing a catheter into the artery in the liver that feeds the tumor, administering chemotherapeutics and then blocking the artery with embolics in order to kill tumor cells by depriving them of essential oxyge…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Male or female, aged 18 years, meeting criteria for diagnosis of BCLC B HCC and referred to undergo TACE * HCC measuring 3 cm in minimum transverse diameter and meets LI-RADS 5 criteria based on cross-sectional imaging as determined by a board-certified, sub-specialty trained …
Contacts

Terence P Gade, MD PhD

(215) 823-5800

Terence.Gade@va.gov

CONTACT